Abstract
Aims Diabetic retinopathy (DR) is the most common cause of vision loss in the working age. This research aimed to develop a machine learning model which can predict the development of referrable DR from fundus imagery of otherwise healthy eyes.
Methods Our researchers trained a machine learning algorithm on the EyePacs dataset, consisting of 156,363 fundus images. Referrable DR was defined as any level above mild on the International Clinical Diabetic Retinopathy scale.
Results The algorithm achieved 0.81 Area Under Receiver Operating Curve (AUC) when averaging scores from multiple images on the task of predicting development of referrable DR, and 0.76 AUC when using a single image.
Conclusion Our results suggest that risk of DR may be predicted from fundus photography alone. Prediction of personalized risk of DR may become key in treatment and contribute to patient compliance across the board, particularly when supported by further prospective research.
Synopsis The deep learning algorithm our researchers developed was able to predict the development of referrable diabetic retinopathy in diabetic patients with otherwise healthy eyes with 0.81 AUC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by AEYE Health Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Sterling IRB Chairman (or designee) has determined that the study is exempt from IRB review pursuant to the terms of the U.S. Department of Health and Human Service's Policy for Protection of Human Research Subjects at 45 C.F.R. 46.104(d). Sterling IRB has determined that category 4 exemption applies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated review and sources
Data Availability
All data produced in the present study is proprietary. Anonymized patient IDs are available upon request to the authors.
